- Home
- DXC vs GLPG Comparison
DXC vs GLPG Comparison
Compare DXC & GLPG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DXC
- GLPG
- Stock Information
- Founded
- DXC 1959
- GLPG 1999
- Country
- DXC United States
- GLPG Belgium
- Employees
- DXC N/A
- GLPG N/A
- Industry
- DXC EDP Services
- GLPG Biotechnology: Pharmaceutical Preparations
- Sector
- DXC Technology
- GLPG Health Care
- Exchange
- DXC Nasdaq
- GLPG Nasdaq
- Market Cap
- DXC 2.6B
- GLPG 2.1B
- IPO Year
- DXC N/A
- GLPG 2005
- Fundamental
- Price
- DXC $13.60
- GLPG $31.95
- Analyst Decision
- DXC Hold
- GLPG Hold
- Analyst Count
- DXC 6
- GLPG 4
- Target Price
- DXC $15.60
- GLPG $30.00
- AVG Volume (30 Days)
- DXC 1.6M
- GLPG 285.3K
- Earning Date
- DXC 10-30-2025
- GLPG 11-05-2025
- Dividend Yield
- DXC N/A
- GLPG N/A
- EPS Growth
- DXC 384.35
- GLPG N/A
- EPS
- DXC 2.05
- GLPG N/A
- Revenue
- DXC $12,794,000,000.00
- GLPG $323,674,692.00
- Revenue This Year
- DXC N/A
- GLPG $1.77
- Revenue Next Year
- DXC N/A
- GLPG $0.44
- P/E Ratio
- DXC $6.62
- GLPG N/A
- Revenue Growth
- DXC N/A
- GLPG 5.43
- 52 Week Low
- DXC $12.24
- GLPG $22.36
- 52 Week High
- DXC $24.83
- GLPG $37.78
- Technical
- Relative Strength Index (RSI)
- DXC 51.57
- GLPG 41.51
- Support Level
- DXC $12.63
- GLPG $31.06
- Resistance Level
- DXC $13.46
- GLPG $32.62
- Average True Range (ATR)
- DXC 0.38
- GLPG 0.81
- MACD
- DXC 0.05
- GLPG -0.39
- Stochastic Oscillator
- DXC 90.69
- GLPG 21.80
About DXC DXC Technology Company
DXC Technology Co is a vendor-independent IT services provider. The company's operating segment includes Global Business Services (GBS) and Global Infrastructure Services (GIS). It generates maximum revenue from the GIS segment. GIS offerings include Cloud and Security; IT Outsourcing and Modern Workplace. Geographically, it derives a majority of revenue from the Other Europe region.
About GLPG Galapagos NV
Galapagos NV is a fully integrated biotechnology company with operations in Europe and the United States, dedicated to developing medicines focusing on oncology and immunology. The group focuses on unmet medical needs, it synergizes compelling science, technology, and collaborative approaches to create a deep pipeline of medicines. Its clinical pipeline includes: GLPG5101, a CD19 CAR-T product candidate decentralized manufactured, currently in Phase 1/2 in rrNHL; GLPG5301, a BCMA CAR-T product candidate decentralized manufactured, currently in Phase 1 in rrMM; and GLPG3667, a TYK2 inhibitor currently in Phase 2 clinical trial in DM and SLE. It derives maximum revenue from the United States of America.